Overview

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

A randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative recurrence-free survival. In this study, we aim to compare the prognosis in intrahepatic cholangiocarcinoma between Toripalimab combined with leventinib and GEMOX neoadjuvant treatment and the current clinical surgical treatment (traditional group).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Collaborators:

RenJi Hospital
Shanghai 6th People's Hospital
Shanghai Public Health Clinical Center
Shenzhen University General Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine